Similar articles for PMID: 32014032

Year	Number of Results
1990	1
1997	2
1998	1
1999	2
2000	2
2001	1
2002	2
2004	1
2005	2
2006	2
2007	2
2008	2
2009	5
2010	3
2011	4
2012	7
2013	11
2014	8
2015	9
2016	4
2017	12
2018	11
2019	6
2020	18
2021	19
2022	14
2023	5
2024	0

1

Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study.

Chabriat H, Bassetti CL, Marx U, Picarel-Blanchot F, Sors A, Gruget C, Saba B, Wattez M, Audoli ML, Hermann DM. Chabriat H, et al. Trials. 2020 Feb 3;21(1):136. doi: 10.1186/s13063-020-4072-2. Trials. 2020. PMID: 32014032 Free PMC article. Clinical Trial.

2

Safety and efficacy of GABA_A α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial.

Chabriat H, Bassetti CL, Marx U, Audoli-Inthavong ML, Sors A, Lambert E, Wattez M, Hermann DM; RESTORE BRAIN study investigators. Chabriat H, et al. Lancet Neurol. 2020 Mar;19(3):226-233. doi: 10.1016/S1474-4422(20)30004-1. Lancet Neurol. 2020. PMID: 32085836 Clinical Trial.

3

Persistent therapeutic effect of a novel α5-GABA_A receptor antagonist in rodent preclinical models of vascular cognitive impairment.

Gacsályi I, Móricz K, Gigler G, Megyeri K, Machado P, Antoni FA. Gacsályi I, et al. Eur J Pharmacol. 2018 Sep 5;834:118-125. doi: 10.1016/j.ejphar.2018.07.015. Epub 2018 Jul 21. Eur J Pharmacol. 2018. PMID: 30012500

4

Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke.

Gulati A, Agrawal N, Vibha D, Misra UK, Paul B, Jain D, Pandian J, Borgohain R. Gulati A, et al. CNS Drugs. 2021 Jan;35(1):85-104. doi: 10.1007/s40263-020-00783-9. Epub 2021 Jan 11. CNS Drugs. 2021. PMID: 33428177 Free PMC article. Clinical Trial.

5

Postacute Delivery of GABA_A α5 Antagonist Promotes Postischemic Neurological Recovery and Peri-infarct Brain Remodeling.

Wang YC, Dzyubenko E, Sanchez-Mendoza EH, Sardari M, Silva de Carvalho T, Doeppner TR, Kaltwasser B, Machado P, Kleinschnitz C, Bassetti CL, Hermann DM. Wang YC, et al. Stroke. 2018 Oct;49(10):2495-2503. doi: 10.1161/STROKEAHA.118.021378. Stroke. 2018. PMID: 30355106 Free PMC article.

6

Effects of the Selective α5-GABAAR Antagonist S44819 on Excitability in the Human Brain: A TMS-EMG and TMS-EEG Phase I Study.

Darmani G, Zipser CM, Böhmer GM, Deschet K, Müller-Dahlhaus F, Belardinelli P, Schwab M, Ziemann U. Darmani G, et al. J Neurosci. 2016 Dec 7;36(49):12312-12320. doi: 10.1523/JNEUROSCI.1689-16.2016. J Neurosci. 2016. PMID: 27927951 Free PMC article. Clinical Trial.

7

Rationale and design to assess the efficacy and safety of HT047 in patients with acute ischemic stroke: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase II trial.

Heo SH, Song J, Kim BJ, Kim H, Chang DI; HT047 investigators. Heo SH, et al. Medicine (Baltimore). 2019 Oct;98(43):e17655. doi: 10.1097/MD.0000000000017655. Medicine (Baltimore). 2019. PMID: 31651889 Free PMC article. Clinical Trial.

8

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.

Elkins J, Veltkamp R, Montaner J, Johnston SC, Singhal AB, Becker K, Lansberg MG, Tang W, Chang I, Muralidharan K, Gheuens S, Mehta L, Elkind MSV. Elkins J, et al. Lancet Neurol. 2017 Mar;16(3):217-226. doi: 10.1016/S1474-4422(16)30357-X. Epub 2017 Feb 15. Lancet Neurol. 2017. PMID: 28229893 Clinical Trial.

9

Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial.

Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, Röther J, Witte OW, Hamann G, Junghans U, Villringer A, Fiebach JB. Siebler M, et al. Stroke. 2011 Sep;42(9):2388-92. doi: 10.1161/STROKEAHA.110.599662. Epub 2011 Aug 18. Stroke. 2011. PMID: 21852609 Clinical Trial.

10

Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.

Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Grønning BA, Chabriat H, Chang KC, Davalos AE, Ford GA, Grotta J, Kaste M, Schwamm LH, Shuaib A; DIAS-3 Investigators. Albers GW, et al. Lancet Neurol. 2015 Jun;14(6):575-84. doi: 10.1016/S1474-4422(15)00047-2. Epub 2015 Apr 30. Lancet Neurol. 2015. PMID: 25937443 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

145 results

Results by year